Evidence map›Paper›PMID 24821801›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.

Kalani Halemano, Kejun Guo, Karl J Heilman, Bradley S Barrett, Diana S Smith, Kim J Hasenkrug, Mario L Santiago

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Inactivation of GSK3β by SerCell death and differentiation · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Immunoglobulin Classification Using the Colored Antibody Graph.Journal of computational biology : a journal of computational molecular cell biology · 2016
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kalani HalemanoDepartments of Medicine andMicrobiology and Immunology, University of Colorado Denver, Aurora, CO 80045; and.
Kejun GuoDepartments of Medicine and.
Karl J HeilmanDepartments of Medicine and.
Bradley S BarrettDepartments of Medicine and.
Diana S SmithDepartments of Medicine and.
Kim J HasenkrugLaboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840.
Mario L SantiagoDepartments of Medicine andMicrobiology and Immunology, University of Colorado Denver, Aurora, CO 80045; and mario.santiago@ucdenver.edu.
University of Colorado Denver · USNational Institute of Allergy and Infectious Diseases · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
Immunology And Pathology Of Acute Murine Leukemia Virus InfectionsZIAAI000753 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2022
$8.1M
Immunology and Pathology of Chronic Murine Leukemia Virus InfectionsZIAAI001100 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HASENKRUG, KIM · 2009 to 2015
$3.1M
Innate Restriction Factor Modulation of Retrovirus-specific Humoral ImmunityR01AI090795 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2010 to 2013
$2.8M
APOBEC3/Rfv3 and Immunoglobulin Somatic HypermutationR01AI116603 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2016 to 2020
$2.5M
Apobec3 and the Neutralizing Antibody Response Against Pathogenic RetrovirusesR56AI084123 · NIAID · UNIVERSITY OF COLORADO DENVER · PI SANTIAGO, MARIO LUIS · 2009 to 2009
$658k
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI090795NIAID NIH HHS R01 AI116603NIAID NIH HHS R56 AI084123
6 · The paper itself

Abstract

Somatic hypermutation (SHM) is an integral process in the development of high-affinity antibodies that are important for recovery from viral infections and vaccine-induced protection. Ig SHM occurs predominantly in germinal centers (GC) via the enzymatic activity of activation-induced deaminase (AID). In contrast, the evolutionarily related apolipoprotein B mRNA-editing enzyme, catalytic polypeptide 3 (APOBEC3) proteins are known to restrict retroviruses, including HIV-1. We previously reported that mouse APOBEC3 encodes Recovery from Friend virus 3 (Rfv3), a classical resistance gene in mice that promotes the neutralizing antibody response against retrovirus infection. We now show that APOBEC3/Rfv3 complements AID in driving Ig SHM during retrovirus infection. Analysis of antibody sequences from retrovirus-specific hybridomas and GC B cells from infected mice revealed Ig heavy-chain V genes with significantly increased C-to-T and G-to-A transitions in wild-type as compared with APOBEC3-defective mice. The context of the mutations was consistent with APOBEC3 but not AID mutational activity. These findings help explain the role of APOBEC3/Rfv3 in promoting the neutralizing antibody responses essential for recovery from retroviral infection and highlight APOBEC3-mediated deamination as a previously unidentified mechanism for antibody diversification in vivo.

Indexed as

AICDA (Activation-Induced Cytidine Deaminase)AnimalsAntibodies, NeutralizingAntibodies, ViralBase SequenceB-LymphocytesCytidine DeaminaseGerminal CenterMiceMolecular Sequence DataRetroviridae InfectionsSequence Analysis, DNASomatic Hypermutation, ImmunoglobulinSpleenAICDA (Activation-Induced Cytidine Deaminase)Antibodies, NeutralizingAntibodies, ViralApobec3 protein, mouseCytidine Deaminaseaffinity maturationantibody repertoire profilingFriend retrovirushumoral immunityrestriction factor

Identifiers

PMID24821801
PMCPMC4040588
OpenAlexW2058543428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.